Ocugen announce Phase 3 enrolment completion for OCU400, the largest gene agnostic therapy trial for RP
Biotechnology company Ocugen has announced the enrolment completion of their phase 3 clinical trial for OCU400.
Search results
Biotechnology company Ocugen has announced the enrolment completion of their phase 3 clinical trial for OCU400.
At Retina UK we get many queries from those overseas affected by inherited retinal dystrophies (IRDs). Understandably, many want to know about research and how they can get involved. Retina UK does not organise trials or directly recruit participants.
The latest research news piece from Retina UK.
The latest research news piece from Retina UK.
X-linked inheritance means that the faulty gene is located on the X chromosome, the larger of the two sex chromosomes.
Ascidian Therapeutics has announced the completion of the adult dose escalation portion of the STELLAR phase 1/2 clinical trial of ACDN-01 for Stargardt disease, and expansion of the STELLAR study to paediatric participants over 12 years of age.
A recently published study has provided the first molecular map of the mutation-specific changes that occur in the retina which lead to Congenital Stationary Night Blindness.
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
Ground-breaking research is our best hope of delivering new treatments for inherited sight loss. Since 1976, Retina UK has committed more than £18 million to funding innovative research, supporting talented scientists to explore bold new ideas and drive forward discoveries that could transform lives.
A new study by researchers from Radboud University Medical Centre and the University of Basel has uncovered new genetic causes of Retinitis Pigmentosa (RP) that were once overlooked.